Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
13.08
-1.21 (-8.47%)
At close: Feb 6, 2025, 4:00 PM
13.00
-0.08 (-0.61%)
After-hours: Feb 6, 2025, 4:10 PM EST
Oruka Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
457.78M
Revenue Chart
* The company reports in USD currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 46.86M | 42.97M | 1,105.27% |
Dec 31, 2006 | 3.89M | 3.34M | 613.39% |
Dec 31, 2005 | 545.00K | 350.00K | 179.49% |
Dec 31, 2004 | 195.00K | -829.00K | -80.96% |
Dec 31, 2003 | 1.02M | -24.53M | -95.99% |
Dec 31, 2002 | 25.55M | 964.00K | 3.92% |
Dec 31, 2001 | 24.59M | 8.99M | 57.59% |
Dec 31, 2000 | 15.60M | 9.21M | 143.93% |
Dec 31, 1999 | 6.40M | -3.19M | -33.30% |
Dec 31, 1998 | 9.59M | 3.39M | 54.70% |
Dec 31, 1997 | 6.20M | 5.77M | 1,355.16% |
Dec 31, 1996 | 426.00K | -1.70M | -79.97% |
Dec 31, 1995 | 2.13M | 2.08M | 4,154.00% |
Dec 31, 1994 | 50.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Walmart | 673.82B |
Amazon.com | 620.13B |
Apple | 395.76B |
Berkshire Hathaway | 369.89B |
Alphabet | 350.02B |
Microsoft | 261.80B |
Meta Platforms | 164.50B |
NVIDIA | 113.27B |
ORKA News
- 7 weeks ago - Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody - GlobeNewsWire
- 7 weeks ago - Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI) - GlobeNewsWire
- 3 months ago - Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Oruka Therapeutics to Present at Multiple November Investor Conferences - GlobeNewsWire
- 4 months ago - Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress - GlobeNewsWire
- 5 months ago - Oruka Therapeutics Announces $200 Million Private Placement - GlobeNewsWire
- 5 months ago - ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split - GlobeNewsWire
- 5 months ago - ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics - GlobeNewsWire